Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer

• M. D. Torregrosa-Maicas ^[1] ; S. del Barco-Berrón ^[2] ; A. Cotes-Sanchís ^[3] ; L. Lema-Roso ^[4] ; S. Servitja-Tormo ^[5] ; R. Gironés-Sarrió ^[6]
  1. [1] Oncogeriatric Section, Sociedad Española de Oncología Médica (SEOM), Doctor Peset University Hospital, Avda. de Gaspar Aguilar, 90, 46017, Valencia, Spain
  2. [2] Oncogeriatric Section, Sociedad Española de Oncología Médica (SEOM), Doctor Josep Trueta University Hospital, Insituto Catalán de Oncología (ICO), Girona, Spain
  3. [3] Oncogeriatric Section, Sociedad Española de Oncología Médica (SEOM), Elda-Virgen de La Salud University Hospital, Alicante, Spain
  4. [4] Grupo Cooperativo de Investigación Clínica en Cáncer de Mama (SOLTI), Doce de Octubre University Hospital, Madrid, Spain
  5. [5] Grupo Español de Investigación en Cáncer de Mama (GEICAM), Hospital del Mar-Parc de Salut Mar, Barcelona, Spain
  6. [6] Oncogeriatric Section, Sociedad Española de Oncología Médica (SEOM), La Fe University Hospital, Valencia, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 6 (junio), 2022, págs. 1033-1046
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Most patients diagnosed with luminal metastatic breast cancer (MBC) who are seen in oncology consultations are elderly. MBC in elderly patients is characterized by a higher percentage of hormone receptor (HR) expression and a lower expression of human epidermal growth factor receptor 2 (HER2). The decision regarding which treatment to administer to these patients is complex due to the lack of solid evidence to support the decision-making process. The objective of this paper is to review the scientific evidence on the treatment of elderly patients with luminal MBC. For this purpose, the Oncogeriatrics Section of the Spanish Society of Medical Oncology (SEOM), the Spanish Breast Cancer Research Group (GEICAM) and the SOLTI Group appointed a group of experts who have worked together to establish consensus recommendations to optimize the treatment of this population. It was concluded that the chronological age of the patient alone should not guide therapeutic decisions and that a Comprehensive Geriatric Assessment (CGA) should be performed whenever possible before establishing treatment. Treatment selection for the elderly population should consider the patient’s baseline status, the expected benefit and toxicity of each treatment, and the impact of treatment toxicity on the patient’s quality of life and functionality.